Amgen Wraps Up Phase III Trial For Soliris Biosimilar

Amgen Able To Launch Eculizumab Biosimilar In 2025 Under Settlement Agreement

 
• By Rosalind Rei
  
Clinical trial
Amgen has several biosimilars in Phase III development • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products